August Troendle Sells 27,174 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 27,174 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $618.79, for a total transaction of $16,814,999.46. Following the completion of the sale, the chief executive officer owned 561,195 shares in the company, valued at approximately $347,261,854.05. This trade represents a 4.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Medpace Trading Up 1.3%

Shares of NASDAQ MEDP opened at $620.75 on Friday. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The firm has a 50-day moving average of $550.16 and a two-hundred day moving average of $492.71. The company has a market capitalization of $17.33 billion, a price-to-earnings ratio of 36.39, a PEG ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million for the quarter, compared to analysts’ expectations of $689.51 million. During the same quarter in the previous year, the company posted $3.10 EPS. The business’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on MEDP. Jefferies Financial Group cut Medpace from a “buy” rating to a “hold” rating and upped their price target for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Royal Bank Of Canada lifted their target price on Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. BMO Capital Markets boosted their target price on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Mizuho upped their target price on Medpace from $586.00 to $665.00 and gave the company an “outperform” rating in a report on Friday, July 24th. Finally, Weiss Ratings raised Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Three research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $584.18.

Institutional Investors Weigh In On Medpace

Hedge funds have recently made changes to their positions in the company. NewEdge Advisors LLC raised its stake in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock valued at $24,929,000 after buying an additional 3,010 shares during the period. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares in the last quarter. Sivia Capital Partners LLC acquired a new stake in Medpace during the 2nd quarter worth about $296,000. Finally, M&T Bank Corp grew its stake in Medpace by 3.4% during the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after acquiring an additional 31 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest earnings exceeded expectations, with quarterly EPS of $4.25 versus the $3.98 consensus estimate and revenue of $707.33 million versus $689.51 million expected. Revenue increased 17.2% year over year, while management maintained fiscal 2026 EPS guidance of $17.25 to $17.95. Why Is Medpace Up Since Its Last Earnings Report?
• Neutral Sentiment: Analyst sentiment remains mostly cautious. Three analysts rate Medpace a Buy and 10 rate it Hold, with a consensus price target of $584.18. Several firms raised their targets following the earnings report, but those targets remain below the stock’s recent trading level. Medpace Analyst Ratings and Price Targets
• Negative Sentiment: Several insiders sold shares on August 19–20. CEO August J. Troendle sold 42,783 shares for roughly $26.3 million, reducing his holdings by about 7% across the reported transactions. Directors Brian T. Carley and Fred B. Davenport Jr. sold 5,000 and 7,283 shares, respectively, reducing their positions by approximately 15% and 66%. While insider sales do not necessarily indicate deteriorating fundamentals, the cluster of transactions may weigh on investor sentiment. Medpace Insider Buying and Selling
• Negative Sentiment: Valuation is demanding, with Medpace trading at approximately 36 times earnings and a PEG ratio of 2.73. The stock is also near the upper end of its 52-week range, increasing sensitivity to profit-taking and any slowdown in growth.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.